B Staels

Summary

Affiliation: Institut Pasteur de Lille
Country: France

Publications

  1. ncbi Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Bart Staels
    Department of Atherosclerosis, Unité INSERM 545 Institut Pasteur, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Diabetes 54:2460-70. 2005
  2. ncbi Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia
    Roxane M Mansouri
    INSERM, U545, Institut Pasteur de Lille, Lille F 59019, France
    Circ Res 103:450-3. 2008
  3. ncbi Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects
    Gael Bories
    Universite Lille Nord de France, Lille, France
    Diab Vasc Dis Res 9:189-95. 2012
  4. ncbi General molecular biology and architecture of nuclear receptors
    Michal Pawlak
    University of Lille Nord de France, F 59000 Lille, France
    Curr Top Med Chem 12:486-504. 2012
  5. ncbi Peroxisome proliferator-activated receptor-γ activation induces 11β-hydroxysteroid dehydrogenase type 1 activity in human alternative macrophages
    Giulia Chinetti-Gbaguidi
    Universite Lille Nord de France, Lille, France
    Arterioscler Thromb Vasc Biol 32:677-85. 2012
  6. ncbi Plasma bile acids are not associated with energy metabolism in humans
    Gemma Brufau
    Dept, of Pediatrics, Center for Liver, Digestive and Metabolic Diseases, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
    Nutr Metab (Lond) 7:73. 2010
  7. ncbi Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle
    Matjaz Simoncic
    University of Ljubljana, Biotechnical Faculty, Department of Animal Science, Groblje 3, 1230 Domzale, Slovenia
    BMC Genomics 12:96. 2011
  8. ncbi Regulation of lipid and lipoprotein metabolism by retinoids
    B Staels
    Departement d Atherosclerose, INSERM U325, Institut Pasteur de Lille, i rue Calmette, 59019 Lille, France
    J Am Acad Dermatol 45:S158-67. 2001
  9. ncbi Bile acid sequestrants and the treatment of type 2 diabetes mellitus
    Bart Staels
    Institut Pasteur de Lille, Lille, France
    Drugs 67:1383-92. 2007
  10. ncbi Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall
    G Chinetti
    U 325 INSERM, Institut Pasteur de Lille 1, rue Calmette BP245, 59019 Lille, France
    Z Kardiol 90:125-32. 2001

Detail Information

Publications151 found, 100 shown here

  1. ncbi Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Bart Staels
    Department of Atherosclerosis, Unité INSERM 545 Institut Pasteur, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Diabetes 54:2460-70. 2005
    ..The functions of a third PPAR isoform, PPARdelta, and its potential as a therapeutic target are currently under investigation...
  2. ncbi Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia
    Roxane M Mansouri
    INSERM, U545, Institut Pasteur de Lille, Lille F 59019, France
    Circ Res 103:450-3. 2008
    ..These results identify an atheroprotective role of hApoA5 in a mouse model of mixed dyslipidemia...
  3. ncbi Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects
    Gael Bories
    Universite Lille Nord de France, Lille, France
    Diab Vasc Dis Res 9:189-95. 2012
    ..Thus PBMCs in obesity are programmed, which may contribute to the inflammatory dysregulation and increased susceptibility to inflammatory diseases in these patients...
  4. ncbi General molecular biology and architecture of nuclear receptors
    Michal Pawlak
    University of Lille Nord de France, F 59000 Lille, France
    Curr Top Med Chem 12:486-504. 2012
    ..Currently, numerous nuclear receptor ligand analogs are used in therapy or are tested in clinical trials against various diseases such as hypertriglyceridemia, atherosclerosis, diabetes, allergies and cancer and others...
  5. ncbi Peroxisome proliferator-activated receptor-γ activation induces 11β-hydroxysteroid dehydrogenase type 1 activity in human alternative macrophages
    Giulia Chinetti-Gbaguidi
    Universite Lille Nord de France, Lille, France
    Arterioscler Thromb Vasc Biol 32:677-85. 2012
    ..In this study, we investigated the impact of macrophage polarization on the expression and activity of 11β-HSD1 and the role of PPARγ therein...
  6. ncbi Plasma bile acids are not associated with energy metabolism in humans
    Gemma Brufau
    Dept, of Pediatrics, Center for Liver, Digestive and Metabolic Diseases, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
    Nutr Metab (Lond) 7:73. 2010
    ..Therefore, our data do not support an important role of circulating BA in the control of human energy metabolism...
  7. ncbi Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle
    Matjaz Simoncic
    University of Ljubljana, Biotechnical Faculty, Department of Animal Science, Groblje 3, 1230 Domzale, Slovenia
    BMC Genomics 12:96. 2011
    ....
  8. ncbi Regulation of lipid and lipoprotein metabolism by retinoids
    B Staels
    Departement d Atherosclerose, INSERM U325, Institut Pasteur de Lille, i rue Calmette, 59019 Lille, France
    J Am Acad Dermatol 45:S158-67. 2001
    ..Dyslipidemia is a common side-effect of therapy with the currently available retinoids. This review summarizes our current understanding of the molecular mechanisms of regulation of lipid and lipoprotein metabolism by retinoids...
  9. ncbi Bile acid sequestrants and the treatment of type 2 diabetes mellitus
    Bart Staels
    Institut Pasteur de Lille, Lille, France
    Drugs 67:1383-92. 2007
    ..In this article, we review the relationship between bile acid metabolism and glucose homeostasis, and present data demonstrating the utility of bile acid sequestrants in the management of diabetes...
  10. ncbi Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall
    G Chinetti
    U 325 INSERM, Institut Pasteur de Lille 1, rue Calmette BP245, 59019 Lille, France
    Z Kardiol 90:125-32. 2001
    ..In this review, we summarize the evidence indicating that PPAR alpha and PPAR gamma directly modulate vessel wall functions, and its consequences in the control of cardiovascular disease...
  11. ncbi PPAR agonists and the metabolic syndrome
    Bart Staels
    Institut Pasteur de Lille, Departement d Atherosclerose, INSERM U545, Lille, France
    Therapie 62:319-26. 2007
    ..This review will highlight the emerging evidence for the beneficial effects of PPAR agonists in the prevention and treatment of atherosclerosis in such high-risk patients...
  12. ncbi Metformin and pioglitazone: Effectively treating insulin resistance
    Bart Staels
    Institut Pasteur de Lille Département d Athérosclérose, Inserm U545 and Université de Lille 2, Lille, France
    Curr Med Res Opin 22:S27-37. 2006
    ..This provides an opportunity for complementary beneficial effects in the treatment of type 2 diabetes and on the potential consequences of insulin resistance, such as dyslipidemia and atherosclerosis...
  13. ncbi Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
    Bart Staels
    Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France
    Nat Clin Pract Cardiovasc Med 5:542-53. 2008
    ....
  14. ncbi A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus
    Bart Staels
    Universite Lille Nord de France, INSERM U545, UDSL, Lille, France
    Postgrad Med 121:25-30. 2009
    ..This article reviews the role for bile acids in glucose regulation and discusses the potential mechanism(s) of action for the glycemic effects of bile acid sequestrants...
  15. ncbi [Glitazones and atherosclerosis]
    B Staels
    Departement d Atherosclerose, INSERM U545, Institut Pasteur de Lille, Faculte de Pharmacie, Universite de Lille 2, F 59019 Lille cedex, France
    Ann Endocrinol (Paris) 66:1S24-31. 2005
    ....
  16. ncbi Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease
    Catherine Fievet
    Institut Pasteur, Lille, France
    Curr Atheroscler Rep 11:281-8. 2009
    ..This review discusses our current knowledge of the effectiveness of PPAR-based therapeutics, focusing exclusively on cardiovascular disease in type 2 diabetes mellitus and the future prospects for novel generation of PPAR agonists...
  17. ncbi PPARgamma and atherosclerosis
    B Staels
    Département d Athérosclérose U 545 Inserm, Institut Pasteur de Lille, et Université de Lille2, Lille, France
    Curr Med Res Opin 21:S13-20. 2005
    ..Thiazolidinediones are PPARgamma agonists that are in clinical use for the treatment of type 2 diabetes. Accumulating evidence indicates that thiazolidinediones may exert cardioprotective effects at each stage of atherogenesis...
  18. ncbi EMBO workshop on immunology and metabolism
    Bart Staels
    INSERM U1011, University of Lille Nord de France and Institut Pasteur de Lille, Lille, France
    EMBO Rep 12:386-8. 2011
    ..The meeting brought together approximately 100 scientists to discuss interactions between metabolism and inflammation...
  19. ncbi Bile acid sequestrants for lipid and glucose control
    Bart Staels
    Institut Pasteur de Lille, 1 rue Calmette BP245, 59019, Lille Cedex, France
    Curr Diab Rep 10:70-7. 2010
    ....
  20. ncbi Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
    B Staels
    U325 INSERM, Departement d Atherosclerose, Institut Pasteur, Lille, France
    Nature 393:790-3. 1998
    ....
  21. ncbi Regulation of apo A-I gene expression by fibrates
    B Staels
    U 325 INSERM, Departement d Atherosclerose, Institut Pasteur de Lille, France
    Atherosclerosis 137:S19-23. 1998
    ....
  22. ncbi Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells
    V Clavey
    INSERM U325, Institut Pasteur de Lille et Faculté de Pharmacie, Universite Lille 2, Lille, France
    Cell Physiol Biochem 9:139-49. 1999
    ..In conclusion, fibrates down-regulate apo CIII gene expression in human HepG2 cells, most likely via PPARalpha but not via PPARgamma. However, these effects are only observed in HepG2 cells cultured under appropriate conditions...
  23. ncbi Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
    G Martin
    U 325 INSERM, Departement d Atherosclerose, Institut Pasteur, 59019 Lille, France
    J Biol Chem 272:28210-7. 1997
    ..Most interestingly, thiazolidinedione antidiabetic agents seem to favor adipocyte-specific FA uptake relative to muscle, perhaps underlying in part the beneficial effects of these agents on insulin-mediated glucose disposal...
  24. ncbi The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response
    P Delerive
    INSERM U325, , Institut Pasteur de Lille, France
    EMBO Rep 2:42-8. 2001
    ..Taken together, these data identify ROR alpha1 as a potential target in the treatment of chronic inflammatory diseases, including atherosclerosis and rheumatoid arthritis...
  25. ncbi Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
    G Chinetti
    U 325 INSERM, Departement d Atherosclerose, Institut Pasteur, 1 rue Calmette, 59019 Lille, France
    J Biol Chem 273:25573-80. 1998
    ..These data demonstrate a novel function of PPAR in human macrophages with likely consequences in inflammation and atherosclerosis...
  26. ncbi Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I
    G Martin
    , , , Universite de Lille II, Lille, France
    J Clin Invest 107:1423-32. 2001
    ..Because cotreatment with statins and fibrates activated PPARalpha in a synergistic manner, these observations provide a molecular basis for combination treatment with statins and fibrates in coronary heart disease...
  27. ncbi Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil
    J Dallongeville
    Departement d Atherosclerose, INSERM U 508, and INSERM U 325, Institut Pasteur de Lille, 59019 Lille, France
    J Biol Chem 276:4634-9. 2001
    ..Altogether, these results show major molecular differences in action between fibrates and fish oil providing a molecular rationale for combination treatment with these compounds...
  28. ncbi Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta
    P Gervois
    , U.545 INSERM, , , 59019 Lille, France
    J Biol Chem 276:33471-7. 2001
    ..These findings identify a novel molecular mechanism of negative gene regulation by PPAR alpha and reveal the direct implication of PPAR alpha in the modulation of the inflammatory gene response in the liver...
  29. ncbi Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages
    G Chinetti
    UR 545 INSERM, Institut Pasteur de Lille and Université de Lille 2, Lille, France
    Circ Res 92:212-7. 2003
    ..In conclusion, our results identify a role for PPARalpha in the control of cholesterol esterification in macrophages, resulting in an enhanced availability of FC for efflux through the ABCA1 pathway...
  30. ncbi Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice
    I P Torra
    U.545 INSERM, , Institut Pasteur de Lille, , , Lille, France
    Curr Opin Lipidol 12:245-54. 2001
    ..Thus, dysregulation of PPAR activity modulates the onset and evolution of metabolic disorders such as dyslipidaemia, obesity and insulin resistance, predisposing to atherosclerosis...
  31. ncbi Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation
    Y Andersson
    U325 INSERM, Departement d Atherosclerose, Institut Pasteur de Lille et Faculté de Pharmacie, Universite de Lille II, Lille, France
    Arterioscler Thromb Vasc Biol 19:115-21. 1999
    ....
  32. ncbi PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages
    B P Neve
    , U.325 INSERM, Institut Pasteur de Lille, , , France
    Circulation 103:207-12. 2001
    ..Our results suggest a novel role for PPARalpha in the control of atherosclerotic plaque thrombogenicity through its effects on TF expression in monocytes and macrophages...
  33. ncbi Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate
    M Bouly
    Department of Atherosclerosis-INSERM U545, Institut Pasteur de Lille, rue du Professeur Calmette, 59019 Lille Cedex, France
    J Biol Chem 276:25841-7. 2001
    ....
  34. ncbi Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages
    G Chinetti-Gbaguidi
    Institut Pasteur de Lille, Lille F 59019, France
    Biochim Biophys Acta 1791:486-93. 2009
    ..In this review, recent advances on the role of the peroxisome proliferator-activated receptor (PPAR) and liver X receptor (LXR) transcription factors in the modulation of macrophage lipid homeostasis will be discussed...
  35. ncbi Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
    P Delerive
    INSERM U325, Departement d Atherosclerose, Institut Pasteur de Lille, 1 rue Pr Calmette 59019 Lille, France
    J Biol Chem 274:32048-54. 1999
    ..Altogether these data indicate that fibrates inhibit the vascular inflammatory response via PPARalpha by interfering with the NF-kappaB and AP-1 transactivation capacity involving direct protein-protein interaction with p65 and c-Jun...
  36. ncbi Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages
    F G Gbaguidi
    UR 545 INSERM and Université de Lille 2, Lille, France
    FEBS Lett 512:85-90. 2002
    ..These actions of PPAR activators are associated with a reduced uptake of glycated LDL and could influence atherosclerosis development associated with diabetes...
  37. ncbi Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR
    G Chinetti
    INSERM U545, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille, France
    Biochem Soc Trans 34:1128-31. 2006
    ..This review will discuss the role of these transcription factors in the control of cholesterol trafficking in macrophages...
  38. ncbi Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR
    G Chinetti
    UR 545 INSERM, , Lille, France
    Biochem Biophys Res Commun 314:151-8. 2004
    ....
  39. ncbi Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages
    G Chinetti-Gbaguidi
    UR 545 INSERM, Institut Pasteur de Lille and Université de Lille 2, Lille, France
    J Lipid Res 46:2717-25. 2005
    ....
  40. ncbi Schistosoma mansoni induces the synthesis of IL-6 in pulmonary microvascular endothelial cells: role of IL-6 in the control of lung eosinophilia during infection
    V Angeli
    Centre d Immunologie et de Biologie Parasitaire, INSERM U547, Institut Pasteur de Lille, Lille, France
    Eur J Immunol 31:2751-61. 2001
    ....
  41. ncbi Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element
    Thierry Claudel
    , , , Institut Pasteur de Lille, , , Lille, France
    J Clin Invest 109:961-71. 2002
    ..FXR bound this site and repressed transcription in a manner independent of retinoid X receptor. The nonsteroidal synthetic FXR agonist GW4064 likewise decreased apoA-I mRNA levels and promoter activity in HepG2 cells...
  42. ncbi Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha
    E Raspe
    U325 INSERM, Institut Pasteur de Lille, 1 rue Calmette, 59019 Lille, France
    J Biol Chem 276:2865-71. 2001
    ..Taken together, our data identify RORalpha as a transcriptional regulator of apo C-III gene expression, providing a novel, physiological role for RORalpha1 in the regulation of genes controlling triglyceride metabolism...
  43. ncbi PPAR alpha, fibrates, lipid metabolism and inflammation
    C Duval
    U.545 INSERM, , Institut Pasteur de Lille, France
    Arch Mal Coeur Vaiss 97:665-72. 2004
    ..Here, we update the potential of PPAR alpha activation in the treatment of metabolic disorders and related cardiovascular complications...
  44. ncbi Therapeutical effects of PPAR agonists assessed by biomarker modulation
    G Chinetti-Gbaguidi
    UR 545 INSERM, Institut Pasteur de Lille, Universite de Lille 2, Lille, France
    Biomarkers 10:S30-6. 2005
    ..This review will focus on the different effects of fibrates and glitazones, as measured by biomarker modulation, on the development of atherosclerosis and cardiovascular disease...
  45. ncbi Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice reduces atherogenesis in response to a high fat-high cholesterol diet
    N Baroukh
    Unité d Expression des Gènes Eucaryotes, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
    FEBS Lett 502:16-20. 2001
    ..In conclusion, we present evidence that the expression of the human gene cluster in mice protects against atherogenesis in response to an atherogenic diet...
  46. ncbi Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
    Thierry Claudel
    UR545 INSERM, Departement d Atherosclerose, Institut Pasteur de Lille, Lille, France
    Gastroenterology 125:544-55. 2003
    ..Apolipoprotein CIII (Apo CIII) is a determinant of serum triglyceride metabolism. In this study, we investigated whether activators of the nuclear farnesoid X receptor (FXR) modulate Apo CIII gene expression...
  47. ncbi The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice
    Bertrand Cariou
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille, F 59019, France
    J Biol Chem 281:11039-49. 2006
    ..This unexpected function of FXR opens new perspectives for the treatment of type 2 diabetes...
  48. ncbi Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway
    A D Edgar
    Department of Atherosclerosis, Laboratoire Fournier, Daix, France
    Toxicol Lett 98:13-23. 1998
    ..This is the first demonstration that cAspAT and AlaAT activities may be pharmacologically altered, independently of a toxic phenomenon...
  49. ncbi Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake
    P de Vos
    Departement d Atherosclerose, Institut Pasteur, Lille, France
    J Biol Chem 270:15958-61. 1995
    ..Modulation of ob expression may therefore constitute a mechanism through which hormonal, pharmacological, or other factors control body weight homeostasis...
  50. ncbi Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme
    Olivier Barbier
    Unité de Recherche 545, Institut National de la Sante et de la Recherche Medicale, Departement d Atherosclerose, Institut Pasteur de Lille and the Faculté de Pharmacie, Universite de Lille II, 59019 Lille, France
    J Biol Chem 278:32852-60. 2003
    ....
  51. ncbi Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease
    M A Bouhlel
    Departement d Atherosclerose, Institut Pasteur de Lille, Lille, France
    J Intern Med 263:28-42. 2008
    ....
  52. ncbi The organization, promoter analysis, and expression of the human PPARgamma gene
    L Fajas
    INSERM U325, Departement d Atherosclerose, Institut Pasteur, F 59019 Lille, France
    J Biol Chem 272:18779-89. 1997
    ....
  53. ncbi The role of fibric acids in atherosclerosis
    J C Fruchart
    , , 2 Inserm U325, Lille, France
    Curr Atheroscler Rep 3:83-92. 2001
    ..Further clinical studies are necessary to investigate if fibric acids decrease cardiovascular mortality in type 2 diabetes and in primary prevention of hypertriglyceridemia and hypolipidemia...
  54. ncbi Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis
    C Fievet
    Institut Pasteur de Lille, Lille, F 59019, France
    Biochem Pharmacol 77:1316-27. 2009
    ..However, LXR activation may also induce undesirable side effects, such as lipogenesis and hypertriglyceridemia. This review discusses the potential to develop LXR modulators as therapeutic agents for atherosclerosis...
  55. ncbi Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells
    P Gosset
    Mécanismes cellulaires et moléculaires de la réaction inflammatoire allergique, INSERM U416, Institut Pasteur de Lille, Lille, France
    Eur J Immunol 31:2857-65. 2001
    ..Taken together, our data suggest that activation of PPARgamma in human DC may have an impact in the orientation of primary and secondary immune responses by favoring type 2 responses...
  56. ncbi Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
    J C Fruchart
    Department of Atherosclerosis, INSERM U325, Pasteur Institute, University of Lille II, France
    Curr Opin Lipidol 10:245-57. 1999
    ....
  57. ncbi Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor
    Ines Pineda Torra
    U 545 Institut National de la Santé et de la Recherche Médicale, Departement d Atherosclerose, Institut Pasteur de Lille, 59019 Lille, France
    Mol Endocrinol 17:259-72. 2003
    ..These results provide molecular evidence for a cross-talk between the FXR and PPARalpha pathways in humans...
  58. ncbi Peroxisome proliferator-activated receptors, orphans with ligands and functions
    K Schoonjans
    U325 INSERM, Departement d Atherosclerose, Institut Pasteur, Lille, France
    Curr Opin Lipidol 8:159-66. 1997
    ..The next few years will be very exciting as additional studies will refine our current knowledge about PPAR alpha and PPAR gamma and may reveal a ligand and role for the lonesome orphan among the PPARs, PPAR delta...
  59. ncbi The role of the orphan nuclear receptor Rev-Erb alpha in adipocyte differentiation and function
    S Laitinen
    UR545 INSERM, Institut Pasteur de Lille, , , 1, rue du Pr Calmette, 59019 Lille, France
    Biochimie 87:21-5. 2005
    ..Future studies on a potential role of Rev-erb alpha on glucose homeostasis and/or inflammation control are thus warranted...
  60. ncbi Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease
    C Lacquemant
    Institute of Biology, CNRS UPRES A 8090, and Pasteur Institute of Lille, 1 rue du Pr Calmette, B P 245, 59019 Lille Cedex, France
    Diabetes Metab 26:393-401. 2000
    ....
  61. ncbi Glucose regulates the expression of the farnesoid X receptor in liver
    Daniel Duran-Sandoval
    Atherosclerosis Department, Unité de Recherche 545 Institute National de la Santé et de la Recherche Médicale, Pasteur Institute of Lille, and Faculty of Pharmacy, Lille2 University, Lille, France
    Diabetes 53:890-8. 2004
    ..In addition, FXR is regulated by glucose likely via the pentose phosphate pathway. Dysregulation of FXR expression may contribute to alterations in lipid and bile acid metabolism in patients with diabetes or insulin resistance...
  62. ncbi Potential regulatory role of the farnesoid X receptor in the metabolic syndrome
    Daniel Duran-Sandoval
    U.R.545 Inserm, , , , 1, rue du Professeur-Calmette, BP245, 59019 Lille, France
    Biochimie 87:93-8. 2005
    ..These observations raise the intriguing possibility for a modulatory role of this receptor also in the metabolic syndrome...
  63. ncbi [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development]
    Daniel Duran-Sandoval
    Inserm U.545, , Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille, France
    Med Sci (Paris) 19:819-25. 2003
    ..In this review, we will discuss the mode of action of fibrates and TZD and we will present an overview on PPAR ligands under development...
  64. ncbi Role of bile acids and bile acid receptors in metabolic regulation
    Philippe Lefebvre
    Institut National de la Sante et de la Recherche Medicale, Lille, France
    Physiol Rev 89:147-91. 2009
    ..Taken together, these findings suggest that modulation of FXR activity and BA metabolism may open new attractive pharmacological approaches for the treatment of the metabolic syndrome and type 2 diabetes...
  65. ncbi Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element
    Ines Pineda Torra
    U 545 Institut National de la Santé et de la Recherche Médicale, Departement d Atherosclerose, Institut Pasteur de Lille, 59019 Lille, France
    Mol Endocrinol 16:1013-28. 2002
    ..Furthermore, these data demonstrate that the hPPARalpha gene is regulated by nuclear receptors, such as HNF-4, COUP-TFII, and PPARalpha...
  66. ncbi PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia
    Nathalie Hennuyer
    INSERM U545, Departement d Atherosclerose, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille Cedex, France
    Arterioscler Thromb Vasc Biol 25:1897-902. 2005
    ....
  67. ncbi Generation and characterization of a humanized PPARδ mouse model
    B Gross
    Universite Lille Nord de France, Lille, France
    Br J Pharmacol 164:192-208. 2011
    ....
  68. ncbi Leptin
    J Auwerx
    Laboratoire de Biologie des Régulations chez les Eucaryotes U325 INSERM, Departement d Atherosclerose, Institut Pasteur, Lille, France
    Lancet 351:737-42. 1998
    ..Human obesity is a complex disorder, with many factors playing a part; the pathophysiology of leptin is not as simple as it seems to be in rodent models of obesity...
  69. ncbi PPARS, metabolic disease and atherosclerosis
    J C Fruchart
    Unité de Recherche sur les Lipoprotéines et l Athérosclérose, Faculte de Pharmacie, INSERM U545, Institut Pasteur et Université de Lille 2, Lille, France
    Pharmacol Res 44:345-52. 2001
    ....
  70. ncbi Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids
    L Berthou
    INSERM U 325, Departement d Atherosclerose, Institut Pasteur, Lille, France
    Eur J Biochem 232:179-87. 1995
    ..In contrast, only fenofibric acid, but not the other fibrates or fatty acids tested, decrease apo A-II gene expression in vitro...
  71. ncbi Peroxisome proliferator-activated receptors in inflammation control
    P Delerive
    U325 INSERM, , Institut Pasteur de Lille, 1 rue Professeur Calmette, 59019 Lille, France
    J Endocrinol 169:453-9. 2001
    ..These recent findings indicate a modulatory role for PPARs in inflammation with potential therapeutical applications in chronic inflammatory diseases...
  72. ncbi Fibrates, glitazones, and peroxisome proliferator-activated receptors
    Fanny Lalloyer
    University Lille Nord de France, Lille, France
    Arterioscler Thromb Vasc Biol 30:894-9. 2010
    ....
  73. ncbi Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha
    Annelise Genoux
    Departement d Atherosclerose, U 545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, Lille Cedex, France
    Arterioscler Thromb Vasc Biol 25:1186-92. 2005
    ..In the present study, we identified the retinoic acid receptor-related orphan receptor-alpha (RORalpha) as a regulator of human APOA5 gene expression...
  74. ncbi DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha
    Philippe Delerive
    , , Institut Pasteur de Lille, 59019 Lille, France
    Mol Endocrinol 16:1029-39. 2002
    ....
  75. ncbi The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene
    Olivier Barbier
    UR 545 INSERM, Departement d Atherosclerose, Institut Pasteur de Lille and the Faculté de Pharmacie, Universite de Lille II, France
    J Biol Chem 278:13975-83. 2003
    ..Furthermore, since UGT1A9 is involved in the catabolism of fibrates, these results suggest that PPAR alpha and PPAR gamma may control the intracellular level of active fibrates...
  76. ncbi PPAR agonists: multimodal drugs for the treatment of type-2 diabetes
    Barbara Gross
    Institut Pasteur de Lille, 1 rue du Prof Calmette, Lille, F 59019, France
    Best Pract Res Clin Endocrinol Metab 21:687-710. 2007
    ..This chapter focuses on the PPAR agonists currently used in the clinic, as well as on the discovery and development of the next generation of PPAR agonists...
  77. ncbi Intestine-specific regulation of PPARalpha gene transcription by liver X receptors
    Sophie Colin
    Institut Pasteur de Lille, Departement d Atherosclerose, Unité 545, Lille, France
    Endocrinology 149:5128-35. 2008
    ..Taken together, these results demonstrate that PPARalpha is an intestine-specific LXR target gene and suggest the existence of a transcriptional cross talk between those members of the nuclear receptor superfamily...
  78. ncbi The nuclear receptors Rev-erbs and RORs integrate circadian rhythms and metabolism
    Hélène Duez
    Institut Pasteur de Lille, 1, rue Calmette, BP 245, F 59019 Lille, France
    Diab Vasc Dis Res 5:82-8. 2008
    ..Moreover, they cross-talk with several other nuclear receptors controlling energy homeostasis. Therefore, Rev-erbalpha and RORalpha may play a central role in the coordination of metabolic processes and circadian outputs...
  79. ncbi Downregulation of the tumour suppressor p16INK4A contributes to the polarisation of human macrophages toward an adipose tissue macrophage (ATM)-like phenotype
    L Fuentes
    Universite Lille Nord de France, F 59000 Lille, France
    Diabetologia 54:3150-6. 2011
    ..In the present study, p16(INK4A) levels in human ATMs and the role of p16(INK4A) in acquiring the ATM phenotype were assessed...
  80. ncbi Schistosoma mansoni schistosomula reduce E-selectin and VCAM-1 expression in TNF-alpha-stimulated lung microvascular endothelial cells by interfering with the NF-kappaB pathway
    F Trottein
    Centre d Immunologie et de Biologie, Parasitaire INSERM U167, Institut Pasteur de Lille, Lille, France
    Eur J Immunol 29:3691-701. 1999
    ..We speculate that this mechanism could represent a new stratagem that parasites may use to escape the immune system by controlling leukocyte recruitment to the lungs...
  81. ncbi PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
    G Chinetti
    Institut Pasteur and U325 INSERM and Université de Lille 2, Lille, France
    Nat Med 7:53-8. 2001
    ..Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages...
  82. ncbi Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications
    G Chinetti
    Institut Pasteur, , Lille, France
    Int J Obes Relat Metab Disord 27:S41-5. 2003
    ....
  83. ncbi Association between liver X receptor alpha gene polymorphisms and risk of metabolic syndrome in French populations
    V Legry
    INSERM, U744, Lille, France
    Int J Obes (Lond) 32:421-8. 2008
    ..The liver X receptor alpha (NR1H3) plays numerous roles in metabolic pathways involved in metabolic syndrome...
  84. ncbi Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis
    Benoit Pourcet
    Institut Pasteur de Lille, , 01 rue du Professeur Calmette, BP 245, Lille 59019, France
    Expert Opin Emerg Drugs 11:379-401. 2006
    ..This review discusses why PPARs and development of novel selective PPAR modulators, dual and pan PPAR agonists constitute promising approaches for the treatment of diabetes, dyslipidaemia and atherosclerosis...
  85. ncbi Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha
    Hélène Duez
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille, France INSERM, U545, Lille, France
    Gastroenterology 135:689-98. 2008
    ..Here, we investigate a potential role for Rev-erbalpha in the control of bile acid metabolism via the regulation of the neutral bile acid synthesis pathway...
  86. ncbi Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans
    Bruno Lefebvre
    Univ Lille Nord de France, Lille, France
    J Clin Invest 120:1454-68. 2010
    ....
  87. ncbi Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation
    Gaetane Woerly
    Institut National de la Sante et de la Recherche Medicale INSERM, U547 IFR17, Institut Pasteur de Lille, France
    J Exp Med 198:411-21. 2003
    ..Thus, PPAR-alpha and -gamma (co)agonists might be of therapeutic interest for the regulation of allergic or inflammatory reactions by targeting both regulatory and effector cells involved in the immune response...
  88. ncbi Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes
    Christophe Blanquart
    INSERM UR 545, Departement d Atherosclerose, Institut Pasteur de Lille, 1 rue du Pr Calmette 59019 Lille, France
    J Biol Chem 277:37254-9. 2002
    ..Regulation of its degradation provides a novel regulatory mechanism of transcriptional activity of this nuclear receptor...
  89. ncbi Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription
    Eric Raspé
    UR 545 INSERM, Institut Pasteur de Lille, 1 rue Calmette, 59019 Lille, France
    J Lipid Res 43:2172-9. 2002
    ..Taken together, our data identify Rev-erbalpha as a regulator of apoC-III gene expression, providing a novel, physiological role for this nuclear receptor in the regulation of lipid metabolism...
  90. ncbi Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha
    Eric Raspé
    UR 545 INSERM, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France
    J Biol Chem 277:49275-81. 2002
    ..Finally, adenoviral overexpression of hRORalpha1 in HepG2 cells led to enhanced hRev-erbalpha mRNA accumulation, further confirming the physiological importance of RORalpha1 in the regulation of Rev-erbalpha expression...
  91. ncbi FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity
    Olivier Barbier
    U545 INSERM, Department of Atherosclerosis, Faculty of Pharmacy, Lille Pasteur Institute and University of Lille II, 1 rue du Pr Calmette, BP 245, 59019 Lille, France
    Gastroenterology 124:1926-40. 2003
    ..The human uridine 5'-diphosphate-glucuronosyltransferase 2B4 (UGT2B4) converts hydrophobic bile acids into more hydrophilic glucuronide derivatives. In this study, we identify UGT2B4 as an FXR target gene...
  92. ncbi Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis
    Lesley J Millatt
    , , Lille, France
    Biochim Biophys Acta 1631:107-18. 2003
    ..However, we also draw attention to the possible undesirable side-effects of LXR activation, and thus the potential interest of developing target gene-specific LXR agonists, or agonists that are specific for only one LXR isoform...
  93. ncbi Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response
    Roxane M Mansouri
    Institut Pasteur de Lille, Departement d Atherosclerose, and Institut National de la Santé et de la Recherche Médicale Unité 545, Lille F59019, France
    Endocrinology 149:3215-23. 2008
    ..In conclusion, we demonstrated that through a specific liver action, PPARalpha behaves as a modulator of systemic inflammation and of the associated vascular response...
  94. ncbi Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment
    Dominique Deplanque
    Laboratoire de Pharmacologie, Universite de Lille 2, Faculté deMédecine, Lille, 59045 France
    J Neurosci 23:6264-71. 2003
    ....
  95. ncbi Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis
    O Barbier
    UR545 INSERM, , Institut Pasteur de Lille, , , Lille, France
    Arterioscler Thromb Vasc Biol 22:717-26. 2002
    ..Thus, by regulating gene transcription, PPARs modulate the onset and evolution of metabolic disorders predisposing to atherosclerosis and exert direct antiatherogenic actions at the level of the vascular wall...
  96. ncbi The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation
    Coralie Fontaine
    UR545 INSERM, Departement d Atherosclerose, 1, rue Calmette, Institut Pasteur de Lille, 59019 Lille, France
    J Biol Chem 278:37672-80. 2003
    ..These results identify Rev-Erbalpha as a target gene of PPARgamma in adipose tissue and demonstrate a role for this nuclear receptor as a promoter of adipocyte differentiation...
  97. ncbi Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms
    Rejane Paumelle
    INSERM U545, Institut Pasteur de Lille, Boulevard du Pr Jules Leclerc, Lille, France
    Trends Cardiovasc Med 18:73-8. 2008
    ..Here we discuss recent data on the cross-talk between statins and PPARalpha agonists and the mechanisms behind these actions...
  98. ncbi Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men
    Elena Rigamonti
    UR 545 INSERM, Institut Pasteur de Lille, 1 rue Calmette BP245, 59019 Lille, France
    Arterioscler Thromb Vasc Biol 28:1050-9. 2008
    ..In this review we will discuss the role of these transcription factors in the control of macrophage activities, with particular attention to species-differences in macrophage function control by PPARs and LXR between rodents and humans...
  99. ncbi Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators
    Ngoc Vu-Dac
    Departement d Atherosclerose, U 545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, 1 rue Calmette BP 245, 59019 Lille Cedex, France
    J Biol Chem 278:17982-5. 2003
    ..These findings demonstrate that APOA5 is a highly responsive peroxisome proliferator-activated receptor alpha target gene and support its role as a major mediator for how fibrates reduce plasma triglycerides in humans...
  100. ncbi The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
    Jean Charles Fruchart
    INSERM UR 545, Universite Lille 2, Lille, France
    Diab Vasc Dis Res 5:319-35. 2008
    ..In conclusion, the R3I highlights the need to address with lifestyle and/or pharmacotherapy the high level of residual vascular risk among dyslipidaemic patients who are treated in accordance with current standards of care...
  101. ncbi Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties
    Natacha Porta
    Department of Pharmacology, Institut de Médecine Prédictive et de Recherche Thérapeutique, Université de Lille 2 et Centre Hospitalier Universitaire, Lille, France
    Epilepsia 50:943-8. 2009
    ..The underlying mechanisms such as PPARalpha activation and others should be investigated. These findings may provide insights into future directions to simplify KD protocols...